Obtain an accurate, real-time snapshot of mutations before initiating treatment
Analyzing mutations in tumor tissue may have considerable drawbacks. Not only is there a risk of complications, but it can take weeks to get results. Numerous clinical trials show that tissue is insufficient for molecular testing in up to 50% of cases.1
Thanks to our highly-sensitive BEAMing technology, a liquid biopsy with OncoBEAM™ requires only a simple blood draw to access tumor DNA and provide a real-time view of a tumor’s mutation status in 5 to 7 days.
OncoBEAM™ assays for NSCLC provide results in just 5 to 7 days from our CLIA-certified laboratory, helping doctors to make faster treatment decisions for patients.
Clinical practice guidelines for the treatment of non-small cell lung cancer (NSCLSC) recommend a combination of EGFR, KRAS, and BRAF testing to provide a comprehensive mutational analysis.2-5 OncoBEAM™ tests for this trifecta of mutations.
EGFR:
Sensitizing Mutations: Del 19, L858R, L861Q
Resistant Mutations: T790M, C797S
EGFR:
Sensitizing Mutations: Del 19, L858R, L861Q
Resistant Mutations: T790M, C797S
KRAS: Codons 12, 13 ,and 61
BRAF: V600E
NSCLC tumors with sensitizing EGFR mutations have increased sensitivity to tyrosine kinase inhibitors (TKIs). Patients who initially respond to TKI therapy frequently relapse, with 60% of those on TKIs developing resistance due to the EGFR T790M mutation.4-5
OncoBEAM™ EGFR can identify the T790M mutation in patients who have progressed on first-line TKI therapy, delivering rapid results and avoiding the need for a repeat tissue biopsy.6
60% of patients on EGFR TKI therapy develop resistance due to the EGFR T790M mutation.7
KRAS mutations occur in 25% of NSCLC cases.8 Independent of therapy, KRAS mutations can indicate poor survival rates compared to tumors without KRAS mutations.
OncoBEAM™ KRAS can identify multiple KRAS mutations, providing a more complete picture of a patient’s condition to rapidly inform critical therapy decisions.
KRAS MUTATIONS OCCUR IN 25% OF NSCLC CASES.8
BRAF mutations are detected in approximately 3% of patients with NSCLC.8 The 2017 NCCN guidelines now include BRAF V600E mutation testing for all newly diagnosed patients in order to inform appropriate administration of first-line therapy, which now includes BRAF targeted therapies.2
OncoBEAM™ BRAF tests for the BRAF V600E mutation, helping doctors to decide whether to initiate first-line therapy as soon as possible.
BRAF MUTATIONS ARE DETECTED IN APPROXIMATELY 3% OF PATIENTS WITH NSCLC.8
A 64-year-old woman was diagnosed with stage IV NSCLC. Her tumor was EGFR positive. She responded well to EGFR TKI therapy with substantial tumor shrinkage and disease stabilization.
Following initial treatment
The OncoBEAM™ solution
OncoBEAM™ EGFR can test for the EGFR T790M mutation amongst multiple sites of disease with a simple blood draw, avoiding the need for an additional tissue biopsy.
Yes. Clinically actionable multigene detection panels are available to assess the mutational status of a tumor.
Not quite. OncoBEAM™ detects mutations in hot spot locations in clinically relevant genes that are indicated in clinical practice guidelines for patient care.
Yes. Plasma mutation status correlates well with response to therapy and there is growing evidence that it can be used to understand tumor activity and disease progression.9, 10
OncoBEAM™ can be used for most cancers where the tumor has accessed the circulatory system and released ctDNA, Multiple tumor types have been shown to shed ctDNA including: lung, colorectal, pancreatic, prostate, breast, melanoma. Certain cancers, such as gliomas, have ctDNA levels that are too low to detect.11
Sysmex Inostics accepts all insurance plans, but OncoBEAM™ tests are currently not in-network with most carriers. We are working to become in-network with payors. Sysmex Inostics directly bills insurance or Medicare and patients are not responsible for any balance that is not covered by insurance or Medicare. Deductibles may apply if applicable. Sysmex Inostics does not accept uninsured or Medicaid patients at this time.
References:
© 2018 Sysmex Inostics, Inc.